Sinovac Biotech, Ltd (SVA) Posts Q2 Loss of 2c/Share

Sinovac Biotech, Ltd (NASDAQ: SVA) reported Q2 EPS of ($0.02), $0.08 better than the analyst estimate of ($0.10). Revenue for the quarter came in at $9.37 million versus the consensus estimate of $8.3 million.

For earnings history and earnings-related data on Sinovac Biotech, Ltd (SVA) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• JPMorgan Upgrades Aviva Plc (AV/:LN) (AIVAF) to Overweight
• Morgan Stanley Upgrades Oil India Ltd. (OINL:IN) to Equalweight
• HSBC Upgrades Pegatron Corp. (4938:TT) to Hold